
With $110M to add to the bankroll, Generation Bio sets its sights on engineering a revolution in the gene therapy field
Whoever comes out on top of the current race to gain pioneering approvals for new AAV-delivered gene therapies will have to look over their shoulders to watch the next tech wave forming on the horizon for gene therapy 2.0.
One of those next-gen players, Generation Bio, just brought in $110 million of venture cash to cover the cost of the rest of their preclinical journey toward something completely new in the field. The latest round brings the biotech — which now has about 80 staffers — up to $235 million in total since its inception about 3 years ago. That will fuel the rest of its preclinical stage of development as it looks to break into human studies in the back half of 2021.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters